Roche's Enicepatide Hits Phase 2 Goals in Diabetes-Obesity, Intensifying GLP-1 Race
VKTX sits 56% above its 52-week low of $24.52 on elevated volume (10× avg).
Summary
Roche's enicepatide met Phase 2 endpoints in Type 2 diabetes with obesity, showing 2.65 percentage point HbA1c reduction and 15.5% weight loss at 48 weeks. This directly challenges Viking's VK2735, which reported positive maintenance data the same day. Roche plans a late-stage cardiovascular outcomes program in H1 2027, signaling deep commitment to the obesity market. For Viking, a well-capitalized competitor with strong data raises the bar for differentiation and partnership appeal. Watch for Viking's Phase 3 VANQUISH readouts and any partnership announcements as competitive pressure mounts.
At the time of this announcement, VKTX was trading at $38.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $24.52 to $43.15. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.